OA10515A - Utilisation du fumagillol et ses dérivés pour préparer des médicaments destinés à combattre les infections intestinales - Google Patents

Utilisation du fumagillol et ses dérivés pour préparer des médicaments destinés à combattre les infections intestinales Download PDF

Info

Publication number
OA10515A
OA10515A OA70088A OA70088A OA10515A OA 10515 A OA10515 A OA 10515A OA 70088 A OA70088 A OA 70088A OA 70088 A OA70088 A OA 70088A OA 10515 A OA10515 A OA 10515A
Authority
OA
OAPI
Prior art keywords
fumagillol
fumagillin
preparation
ester
patients
Prior art date
Application number
OA70088A
Other languages
English (en)
French (fr)
Inventor
Jean-Michel Molina
Francis Derouin
Original Assignee
Sanofi Sa
Assist Publ Hopitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Assist Publ Hopitaux De Paris filed Critical Sanofi Sa
Publication of OA10515A publication Critical patent/OA10515A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
OA70088A 1995-03-27 1997-09-26 Utilisation du fumagillol et ses dérivés pour préparer des médicaments destinés à combattre les infections intestinales OA10515A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9503549 1995-03-27

Publications (1)

Publication Number Publication Date
OA10515A true OA10515A (fr) 2002-04-24

Family

ID=9477436

Family Applications (1)

Application Number Title Priority Date Filing Date
OA70088A OA10515A (fr) 1995-03-27 1997-09-26 Utilisation du fumagillol et ses dérivés pour préparer des médicaments destinés à combattre les infections intestinales

Country Status (25)

Country Link
US (1) US5900431A (cs)
EP (1) EP0817626B1 (cs)
JP (1) JP3260378B2 (cs)
KR (1) KR100286920B1 (cs)
CN (1) CN1072485C (cs)
AP (1) AP646A (cs)
AT (1) ATE172641T1 (cs)
AU (1) AU706161B2 (cs)
CA (1) CA2216623C (cs)
CZ (1) CZ286821B6 (cs)
DE (1) DE69600879T2 (cs)
DK (1) DK0817626T3 (cs)
EA (1) EA000150B1 (cs)
ES (1) ES2128846T3 (cs)
FR (1) FR06C0014I2 (cs)
HU (1) HU224028B1 (cs)
IS (1) IS2048B (cs)
NO (1) NO315968B1 (cs)
NZ (1) NZ304906A (cs)
OA (1) OA10515A (cs)
PL (1) PL183378B1 (cs)
SK (1) SK283883B6 (cs)
TR (1) TR199701048T1 (cs)
UA (1) UA41446C2 (cs)
WO (1) WO1996030010A2 (cs)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900431A (en) * 1995-03-27 1999-05-04 Sanofi Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
HU228857B1 (en) * 1999-02-26 2013-06-28 Sanofi Aventis Stable formulation containing fumagillin
JP3265394B1 (ja) * 2001-03-14 2002-03-11 泰三 矢野 アクリル系樹脂手袋
DE10341887A1 (de) * 2003-09-09 2005-03-31 Leopold Kostal Gmbh & Co. Kg Elektrisches Schaltermodul
FR2886855B1 (fr) * 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
CA2706914A1 (en) * 2007-11-28 2009-06-11 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
EP2317845A4 (en) * 2008-07-18 2011-11-09 Zafgen Inc METHOD FOR TREATING AN OVERWEIGHT OR FATABLE PERSON
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
EP2486004B1 (en) 2009-10-09 2017-05-03 Zafgen, Inc. Sulphone compounds for use in the treatment of obesity
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
EP2521719B1 (en) 2010-01-08 2015-07-29 Zafgen, Inc. Fumagillol type compounds and methods of making and using same
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
BR112013001613A2 (pt) 2010-07-22 2016-05-24 Zafgen Inc compostos tricíclicos e métodos para fazer e usar os mesmos.
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
WO2012075020A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Treatment of obesity using non-daily administration of 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol
MX344238B (es) 2011-01-26 2016-12-07 Zafgen Inc Compuestos de tetrazol y métodos para preparar y usar los mismos.
CA2829204C (en) 2011-03-08 2019-12-24 Zafgen, Inc. Oxaspiro[2.5]octane derivatives and analogs
CA2835195A1 (en) 2011-05-06 2012-11-15 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
CN103764652B (zh) 2011-05-06 2016-03-23 扎夫根股份有限公司 三环吡唑磺酰胺化合物及其制备和使用方法
JP6062423B2 (ja) 2011-05-06 2017-01-18 ザフゲン，インコーポレイテッド 部分飽和三環式化合物ならびにその製造および使用方法
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
AU2013209719A1 (en) 2012-01-18 2014-08-07 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
JP6035347B2 (ja) 2012-01-18 2016-11-30 ザフゲン，インコーポレイテッド 三環式スルホンアミド化合物ならびにその作製および使用方法
EP2847176A1 (en) 2012-05-07 2015-03-18 Zafgen, Inc. Polymorphic salt of the oxalate salt of 6 - o - ( 4 - dimethylaminoethoxy) cinnarnoyl fumagillol and methods of making and using same
WO2013169857A1 (en) 2012-05-08 2013-11-14 Zafgen, Inc. Treating hypothalamic obesity with metap2 inhibitors
JP6177888B2 (ja) 2012-05-09 2017-08-09 ザフゲン，インコーポレイテッド フマギロール型化合物ならびにその製造および使用方法
CN104918615B (zh) 2012-11-05 2018-10-12 扎夫根股份有限公司 治疗肝病的方法
MX2015005733A (es) 2012-11-05 2016-02-10 Zafgen Inc Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
MX2015005732A (es) 2012-11-05 2015-12-16 Zafgen Inc Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
EP2968250B1 (en) 2013-03-14 2019-06-19 Zafgen, Inc. Methods of treating renal disease and other disorders
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
CN106591389B (zh) * 2015-10-15 2019-10-11 中国科学院微生物研究所 一种利用烟曲霉菌生产烟曲霉素的方法
CN105622593B (zh) * 2016-02-25 2018-06-26 中国农业科学院蜜蜂研究所 一种烟曲霉素的提取方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2791530A (en) * 1953-08-31 1957-05-07 Abbott Lab Stabilized fumagillin compositions
JPH0629278B2 (ja) * 1985-06-26 1994-04-20 藤沢薬品工業株式会社 オキサスピロオクタン化合物
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
JPH06504262A (ja) * 1990-07-27 1994-05-19 レブリゲン　コーポレーション 脈管形成性の病気の処置用の新規な方法と組成物
US5328930A (en) 1993-03-01 1994-07-12 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin
US5900431A (en) * 1995-03-27 1999-05-04 Sanofi Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
AU3968597A (en) * 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors

Also Published As

Publication number Publication date
CN1179715A (zh) 1998-04-22
NO315968B1 (no) 2003-11-24
HUP9801220A3 (en) 2001-10-29
ES2128846T3 (es) 1999-05-16
SK283883B6 (sk) 2004-04-06
NZ304906A (en) 1999-06-29
SK130797A3 (en) 1998-03-04
HUP9801220A2 (hu) 1999-09-28
ATE172641T1 (de) 1998-11-15
WO1996030010A2 (fr) 1996-10-03
CN1072485C (zh) 2001-10-10
MX9707150A (es) 1998-07-31
TR199701048T1 (xx) 1998-01-21
CA2216623C (en) 2005-05-31
NO974466D0 (no) 1997-09-26
IS4557A (is) 1997-09-11
AP646A (en) 1998-04-27
AP9701092A0 (en) 1997-10-31
KR100286920B1 (ko) 2001-04-16
KR19980703271A (ko) 1998-10-15
HU224028B1 (hu) 2005-05-30
CZ286821B6 (en) 2000-07-12
DE69600879T2 (de) 1999-06-02
NO974466L (no) 1997-09-26
EP0817626B1 (fr) 1998-10-28
JP3260378B2 (ja) 2002-02-25
IS2048B (is) 2005-09-15
JPH11506421A (ja) 1999-06-08
FR06C0014I1 (cs) 2006-11-17
UA41446C2 (uk) 2001-09-17
DK0817626T3 (da) 1999-07-12
US5900431A (en) 1999-05-04
EA199700267A1 (ru) 1998-04-30
CZ304997A3 (en) 1997-12-17
WO1996030010A3 (fr) 1996-11-28
PL183378B1 (pl) 2002-06-28
FR06C0014I2 (cs) 2006-12-29
AU5278696A (en) 1996-10-16
EP0817626A2 (fr) 1998-01-14
DE69600879D1 (de) 1998-12-03
PL322470A1 (en) 1998-02-02
CA2216623A1 (en) 1996-10-03
AU706161B2 (en) 1999-06-10
EA000150B1 (ru) 1998-10-29

Similar Documents

Publication Publication Date Title
EP0817626B1 (fr) Utilisation du fumagillol et ses derives pour preparer les medicaments destines a combattre les infections intestinales
FR2774591A1 (fr) Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
EP0385846A1 (fr) Composition pharmaceutique à libération prolongée d'acide valproîque
EP0237538B1 (fr) Preparation d'un medicament retard
EP0437128B1 (fr) Utilisation des dérivés des fluoroquinolones pour le traitement de la pneumonie à Pneumocystis carinii
JPH0232093A (ja) 抗レトロウィルスジフルオロ化ヌクレオシド類
US4880742A (en) Prostaglandin biosynthesis inhibitors
WO1991007960A1 (fr) Compositions pharmaceutiques destinees au traitement de l'ataxie et les troubles de l'equilibre
KR20000057628A (ko) 당뇨병환자의 혈관 기능부전 예방을 위한 약제 제조에 있어서카테콜-오-메틸전이효소 억제제의 용도
MXPA97007150A (en) Use of fumagilol and its derivatives to prepare medicines intended to combat intestine infections
EP0555302A1 (en) Method of treating demyelinating disease
CH678275A5 (cs)
FR2675384A1 (fr) Complexes de l'acide polyadenylique avec l'acide polyuridylique.
FR2566664A1 (fr) Composition utile au traitement de la diarrhee contenant du dextromethorphan
EA007488B1 (ru) Фармацевтические композиции с контролируемым высвобождением, содержащие альгинат натрия и альгинат натрия-кальция
FR2618676A1 (fr) Compositions pharmaceutiques antivirales
FR2585573A1 (fr) Medicament pour prevenir l'abus d'alcool
EP0818997A1 (fr) Compositions comprenant l'amiodarone et le betaxolol
FR2684297A1 (fr) Utilisation d'un acide amine soufre pour la preparation d'un medicament destine au traitement de l'eczema.
JPS58210010A (ja) 抗腫瘍剤
FR2527077A1 (fr) Nouveau medicament a base d'un anti-depresseur et d'un alcaloide ergopeptidique